A cluster randomized controlled trial of an adapted U.S. model of pharmaceutical care for nursing home residents in Northern Ireland (fleetwood Northern Ireland study): A cost-effectiveness analysis

Journal of the American Geriatrics Society

Volumn 59, Issue 4, 2011, Pages 586-593

  Patterson, Susan M ^a   Hughes, Carmel M ^a   Cardwell, Chris ^b   Lapane, Kate L ^c   Murray, Ashley M ^d   Crealey, Grainne E ^d  

^a School of Pharmacy   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

Author keywords

cluster randomized controlled trial; cost effectiveness; nursing homes; pharmaceutical care; psychoactive medication

Indexed keywords

AGED; ARTICLE; CLUSTER ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INAPPROPRIATE PRESCRIBING; IRELAND; MAJOR CLINICAL STUDY; MALE; NURSING HOME; NURSING HOME PERSONNEL; PHARMACEUTICAL CARE; PHARMACIST; PRESCRIPTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESIDENCY EDUCATION; UNITED STATES;

AGED, 80 AND OVER; ALGORITHMS; CLUSTER ANALYSIS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IRELAND; MALE; MODELS, THEORETICAL; NURSING HOMES; PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; UNITED STATES;

EID: 79954659162     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03354.x     Document Type: Article

References (40)

1. Rancourt C, Moisan J, Baillargeon L, et al,. Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr 2004; 4: 9-19.
2. McGrath AM, Jackson GA., Survey of neuroleptic prescribing in residents of nursing homes in Glasgow. BMJ 1996; 312: 611-612. (Pubitemid 26079597)
3. Ruths S, Straand J, Nygaard HA., Multidisciplinary medication review in nursing home residents: What are the most significant drug-related problems? The Bergen District Nursing Home (BEDNURS) study. Qual Saf Health Care 2003; 12: 176-180.
4. Commission for Social Care Inspection. Handled with Care? Managing Medication for Residents of Care Homes and Children's Homes-A Follow Up Study. Newcastle: Commission for Social Care Inspection, 2006.
5. Institute of Medicine. Improving the Quality of Care in Nursing Homes. Washington, DC: National Academy Press, 1986.
6. Hughes CM, Lapane K, Mor V., The impact of legislation on nursing home care in the United States: Lessons for the United Kingdom. BMJ 1999; 319: 1060-1063. (Pubitemid 29476440)
7. Hughes CM, Lapane K., Administrative initiatives to reduce inappropriate prescribing of psychotropics in nursing homes: How successful have they been? Drugs Aging 2005; 22: 339-351. (Pubitemid 40656022)
8. Patterson SM, Hughes CM, Crealey G, et al,. An evaluation of an adapted United States model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood NI Study). J Am Geriatr Soc 2010; 58: 44-53.
9. Willan AR, Briggs AH., The Statistical Analysis of Cost-Effectiveness Data. Chichester, UK: Wiley, 2006.
10. Ramsey S, Willke R, Briggs A, et al,. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA task force report. Value Health 2005; 8: 521-533. (Pubitemid 41727304)
11. Drummond M, Sculpher MJ, Torrance GW, et al,. Methods for the Economic Evaluation of Health Care Programmes. 3 edition. Oxford: Oxford University Press, 2005.
12. Glick HA, Doshi JA, Sonnad SS, et al,. Economic Evaluation in Clinical Trials (Handbooks for Health Economic Evaluation). Oxford: Oxford University Press, 2007.
13. Brazier J, Ratcliffe J, Salomon J, et al,. Measuring and Valuing Health Benefits for Economic Evaluation. Oxford: Oxford University Press, 2007.
14. National Insitute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2008.
15. McHorney CA., Measuring and monitoring general health status in elderly persons: Practical and methodological issues in using the SF-36 health survey. Gerontologist 1996; 36: 571-583.
16. Curtis L, Netten A, eds. Unit Costs of Health and Social Care 2005. Canterbury: University of Kent: Personal Social Services Research Unit, 2005.
17. Department of Health. NHS Reference Costs 2004-2005. Leeds: Department of Health, 2006.
18. Northern Ireland Drug Tariff. Available at Accessed April 2010.
19. Patterson SM, Shanks K, Crealey GE, et al,. Multidimensional work sampling (MDWS) of pharmacist activity on a pharmaceutical care services for nursing home residents: A pilot study. Int J Pharm Pract 2006; 14: B58-B59.
20. Fenwick E, Byford S., A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005; 187: 106-108. (Pubitemid 41139681)
21. Morrell CJ, Warner R, Slade P, et al,. Psychological interventions for postnatal depression: Cluster randomised trial and economic evaluation. The PoNDER trial. Health Technol Assess 2009; 13: 1-176.
22. Patterson SM., An evaluation of an adapted United States model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland. PhD thesis, Queen's University Belfast, May 2008.
23. Fulton MM, Allen ER., Polypharmacy in the elderly: A literature review. J Am Acad Nurse Pract 2005; 17: 123-132.
24. Prybys KM., Polypharmacy in the elderly: Clinical challenges in emergency practice. Part 1: Overview, etiology and drug interactions. Emerg Med Rep 2002; 23: 145-153.
25. Bootman JL, Harrison DL, Cox E., The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089-2096. (Pubitemid 27431277)
26. Cameron K, Feinberg J, Lapane K., Fleetwood project Phase III moves forward. Consult Pharm 2002; 17: 181-194.
27. Patterson SM, Hughes CM, Lapane KL., Assessment of a United States pharmaceutical care model for nursing homes in the United Kingdom. Pharm World Sci 2007; 29: 517-525. (Pubitemid 47389409)
28. Cole MR, Jacobs M, Silver B., Unnecessary medications: Cost savings resulting from interdisciplinary assessment of medication regimens. Consult Pharm 1996; 11: 933-936.
29. Christensen D, Trygstad T, Sullivan R, et al,. A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother 2004; 2: 248-256. (Pubitemid 40378779)
30. O'Neill C, Groom L, Avery A, et al,. Age and proximity to death as predictors of GP care costs: Results from a study of nursing home patients. Health Econom 2000; 9: 733-738.
31. Layte R., An analysis of the impact of age and proximity of death on health care costs in Ireland. ESRI Working Paper No. 193 May 2007.
32. Grieve R., Nixon R., Thompson S., Bayesian hierarchical models for cost-effectiveness analysis that use data from cluster randomized trials. Med Decis Making 2010; 30: 163-175.
33. Williamson I, Benge S, Barton S, et al,. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technol Assess 2009; 13: 1-144.
34. Pacini M, Smith RD, Wilson ECF, et al,. Home-based medication review in older people. Is it cost effective? Pharmacoeconomics 2007; 35: 171-180. (Pubitemid 46175552)
35. Bernsten C, Bjorkman I, Caramona M, et al,. Improving the well-being of elderly patients via community pharmacy based provision of pharmaceutical care. Drugs Aging 2001; 18: 63-77. (Pubitemid 32182133)
36. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al,. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005; 165: 1280-1285. (Pubitemid 40989593)
37. Chen Y, Briesacher BA, Field TS, et al,. Unexplained variation across US nursing homes in antipsychotic prescribing rate. Arch Intern Med 2010; 170: 89-95.
38. Banerjee S., Report on the Prescribing of Antipsychotic Drugs to People with Dementia. Time for Action. London: Department of Health, 2009.
39. Kuehn BM., Questionable antipsychotic prescribing remains common, despite serious risks. JAMA 2010; 303: 1582-1584.
40. Godlee F., We need to put the evidence to work. BMJ 2009; 339: b5236.